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ABSTRACT 1 
Background 2 
Numerous studies have identified the potential risk factors and biomarkers for autism 3 
spectrum disorder (ASD). We aim to study the strength and validity of the suggested 4 
environmental risk factors or biomarkers of ASD. 5 
Methods 6 
We conducted an umbrella review and systematically appraised the relevant meta-analyses of 7 
observational studies (PROSPERO registration: CRD42018091704). We searched PubMed, 8 
Embase, and Cochrane Database of Systematic Reviews from inception to 10/17/2018 and 9 
screened the reference list of relevant articles. We obtained the summary effect, 95% 10 
confidence interval (CI), heterogeneity, and 95% prediction intervals. We examined small 11 
study effects and excess significance. We performed analyses under credibility ceilings.  12 
Findings 13 
A total of 46 eligible articles yielded data on 67 environmental risk factors (cases=544212, 14 
population=81708787) and 52 biomarkers (cases=15614, controls=15417). Evidence of 15 
association was convincing for greater maternal age (RR=1·31, 95% CI=1·18 to 1·45), 16 
maternal chronic hypertension (OR=1·48, 95% CI=1·29 to 1·70), maternal gestational 17 
hypertension (OR=1·37, 95% CI=1·21 to 1·54), maternal overweight (RR=1·28, 95% 18 
CI=1·19 to 1·36), preeclampsia (RR=1·32, 95% CI=1·20 to 1·45), pre-pregnancy maternal 19 
antidepressant exposure (RR=1·48, 95% CI=1·29 to 1·71), and selective serotonin reuptake 20 
inhibitor (SSRI) exposure during pregnancy (OR=1·84, 95% CI=1·60 to 2·11). Only two 21 
associations, maternal overweight and SSRI during pregnancy, retained high level of 22 
evidence under subset sensitivity analyses. Evidence from biomarkers was limited. 23 
Interpretation 24 
Convincing evidence suggests that maternal factors such as age and features of metabolic 25 
syndrome are associated with risk of ASD. SSRI use during pregnancy was also convincingly 26 
associated with risk of ASD when exposed and non-exposed groups were compared. 27 
However, there is a possibility that the association is affected by other confounding factors, 28 
considering that pre-pregnancy maternal antidepressant exposure was also convincingly 29 
associated with higher risk of ASD. Findings from prior studies suggest that one possible 30 
confounding factor is underlying maternal psychiatric disorders.  31 
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INTRODUCTION 1 
Autism spectrum disorder (ASD) is a leading cause of disability in children, and often 2 
requires high levels of support, which impose a high cost on society and a substantial 3 
economic, emotional, and physical burden on affected families.1-4 The prevalence of ASD 4 
was estimated to be 2·47% in US children and adolescents,5 and 7·6 per 1000 persons 5 
globally, accounting for 111 disability-adjusted life years per 100000 global population.2 6 
Given limited clinical and epidemiological evidence of remission in ASD,2 numerous 7 
investigations focused to better understand and advance risk prediction and prevention of 8 
ASD. The etiology of ASD is believed to be multifactorial, with various genetic 9 
predispositions and environmental (non-genetic) risk factors having shown to be associated 10 
with an increased risk of ASD.6-11 There have been remarkable advances in the knowledge of 11 
genetic causes of autism by the efforts made in the field of genetics, yet the exact genes are 12 
not clear. In addition, the results on associations of various kinds of environmental factors for 13 
ASD have been inconsistent, and hierarchies of evidence have not been determined across 14 
different factors, while it is unclear if these risk factors are prone to biases.  15 
There have been numerous cohort and case-control studies reporting various kinds of 16 
significant environmental risk factors or biomarkers of ASD, and these have also been meta-17 
analyzed by combining the results of multiple studies.12 However, these analyses are usually 18 
limited to one specific topic, and assessment of various kinds of biases in literature is often 19 
insufficient. Claimed statistically significant associations are susceptible to biases such as 20 
publication bias, reporting bias, and residual confounding bias, resulting in false positives13 21 
or inflated estimates14 of the association. Such problems have resulted in an excess amount of 22 
statistically significant associations (p<0·05) in psychological science and other medical 23 
fields.15,16 Recently, one systematic overview has comprehensively identified and analyzed 24 
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possible environmental risk factors of ASD.7 While this overview was informative, 1 
quantitative assessment of bias was also incomplete because it relied on reports from the 2 
original studies, and definite criteria for determining the credibility of the associations were 3 
lacking. To overcome these limitations, we conducted an umbrella review of the relevant 4 
meta-analyses. We aimed to generate a hierarchy of evidence and examine true 5 
noteworthiness of the suggested environmental risk factors and biomarkers for ASD.  6 
7 
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METHODS 1 
Literature search strategy and eligibility criteria 2 
We followed the pre-specified protocol registered in PROSPERO (registration: 3 
CRD42018091704).17 Three investigators (JYK, MJS, and CYS) searched PubMed, Embase, 4 
and Cochrane Database of Systematic Reviews from inception to 10/17/2018. We used the 5 
following search algorithm: (Asperge* [All Fields] OR autis* [All Fields]) AND meta [All 6 
Fields]. We obtained the eligible articles by consecutively examining the titles, the abstracts, 7 
and then the full-text (figure 1). We further manually searched the references of the relevant 8 
articles and attempted to identify and include eligible studies. Disagreements were resolved 9 
by discussion by JYK, MJS, CYS, and JIS.  10 
We included meta-analyses of observational studies examining associations between ASD 11 
and potential environmental risk factors or biomarkers. The definition of ASD followed that 12 
of the original meta-analysis, while the definition of risk factors and biomarkers followed that 13 
of the World Health Organization.18,19 Biomarkers were defined as any substance, structure, 14 
or process that can be measured in the body or its products and influence or predict the 15 
incidence of outcome or disease.18 Risk factors were defined as any attribute, characteristic or 16 
exposure of an individual that increases the likelihood of developing a disease or injury.19  17 
We screened for articles without language restriction. We only included meta-analyses that 18 
reported either effect estimates of individual study estimates or the data necessary to calculate 19 
these. When two or more meta-analyses existed for an association, we included the most 20 
recent meta-analysis with the largest number of studies. 21 
 22 
Data extraction 23 
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From each meta-analysis, we extracted the first author, publication year, risk factor or 1 
biomarker of interest, number of ASD cases and total participants, maximally adjusted 2 
individual study estimates and corresponding 95% confidence intervals (CI), metrics used for 3 
analyses such as mean difference, Hedges’ g, Cohen’s d, odds ratio (OR), or risk ratio (RR), 4 
and individual study designs (i.e. cohort design, case-control design, etc.).  5 
 6 
Data analysis 7 
We adopted a series of statistical tests, developed and reproduced in previous umbrella 8 
reviews.20-25 We performed re-analysis on each eligible meta-analysis with individual study 9 
estimates extracted from each meta-analysis. We calculated the summary effect size, 95% CI, 10 
and p value of eligible meta-analyses using both fixed and random effects model. Statistical 11 
significance was claimed at p value < 0·05. We further assessed p values below thresholds 12 
such as 10-3 or 10-6.26,27 Additionally, we checked whether the summary effect of the random 13 
effects meta-analysis and the effect of its largest component study (the study with smallest 14 
standard error) showed concordance in terms of statistical significance.20-22,24,25 We also 15 
checked whether the standard error of the largest study is below 0·10, which is considered as 16 
precise effect size.23 We performed Cochran’s Q test and calculated the I2 statistic for 17 
evaluation of heterogeneity.28,29 We estimated the 95% prediction interval, which is the range 18 
where we expect the effect of the association will lie for 95% of similar studies in the 19 
future.30 We assessed the presence of small study effects, i.e. large studies having 20 
significantly more conservative results than smaller studies, with the regression asymmetry 21 
test proposed by Egger et al.31 For statistically significant random effects meta-analysis, we 22 
adopted the test for excess significance bias, which evaluates whether the observed number of 23 
nominally statistically significant studies (p value < 0·05) is too large compared to their 24 
10 
 
 
expected number.32,33 We applied various credibility ceilings to individual observational 1 
studies to account for their potential methodological limitations that might result in spurious 2 
significant results for the meta-analyses.34,35 Details of these analytic methods are further 3 
explained in the supplementary material. All statistical tests were two-sided. The software 4 
used for the analysis was Comprehensive Meta-analysis ver.3.3.070 (Borenstein, NH, USA), 5 
RStudio ver. 1.1.453., and R package “metafor” ver.2.0-0 and “pwr” ver.1.2-2.36-38 6 
 7 
Determining the credibility of evidence 8 
In accordance with previous umbrella reviews,20-25,39,40 we categorized the strength of the 9 
evidence of biomarkers or environmental risk factors for ASD into five levels: convincing 10 
(class I), highly suggestive (class II), suggestive (class III), weak (class IV), and not 11 
significant (NS). Criteria for the level of evidence used p values under random effects model, 12 
the number of ASD cases, heterogeneity presented as I2, small study effects, excess 13 
significance bias, effect estimate under 10% credibility ceiling, and 95% prediction interval 14 
(criteria presented in table 1). For associations classified as convincing or highly suggestive 15 
evidence, we performed four kinds of subset analyses to confirm the robustness of the 16 
associations: We performed subset analyses restricted to prospective cohort studies, cohort 17 
studies, study estimates adjusted for covariates, or component studies that ascertained ASD 18 
cases using diagnostic methods in line with DSM-III/IV/V or ICD-8/9/10 (which are 19 
considered as robust measures compared to other methods such as self-reports). For any 20 
associations based on both cohort study(s) and case-control study(s), we also performed 21 
subgroup analyses, and assessed whether heterogeneity between the effect of the two 22 
subgroups was significant (p value < 0·1 for Cochran’s Q test). We also recorded reports 23 
from meta-analyses and individual studies of differences of effect of environmental risk 24 
11 
 
 
factor of ASD according to important factors such as sex differences and presence of 1 
intellectual disability.  2 
 3 
Role of the funding source 4 
There was no funding source for this study. All authors had full access to all the study data 5 
and the corresponding authors had final responsibility for the decision to submit for 6 
publication. 7 
8 
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RESULTS 1 
A total of 1699 potentially eligible articles were identified by the initial search (figure 1). 2 
After screening by title, abstract, and full-text, 46 articles were thought eligible for our 3 
umbrella review. Fourteen articles were excluded in the full-text screening because a larger 4 
meta-analysis was available (table S1). The eligible 46 articles12,41-85 yielded 119 associations 5 
(67 environmental risk factors and 52 biomarkers). Screening of the reference lists of relevant 6 
articles including a previous systematic review7 did not identify additional eligible articles. A 7 
total of 67 associations of environmental risk factors with ASD was based on data of 544212 8 
cases and a total population of 81708787 (table 1-2, S2-S5). Forty-two associations (63%) 9 
included both cohort and case-control design studies, eight (12%) used cohort design, six 10 
(9%) used case-control designs, and six (9%) included cross-sectional studies. The median 11 
number of study estimates in each analysis was 8 (range 2–24). The median number of cases 12 
and the total population was 3764 and 502843.  13 
Total of 52 (78%) associations showed statistical significance under the random effects 14 
model, of which 33 (49%) had p value < 10-3, and 18 (27%) had p value < 10-6. Fifty-two 15 
(78%) associations had more than 1000 ASD cases, of which 16 were supported by p value < 16 
10-6. Out of 52 statistically significant associations, 40 were also supported by the statistically 17 
significant result of the largest component study, of which 24 were supported by the 18 
statistically significant largest study with standard error < 0·10. Metrics followed that of the 19 
original meta-analyses except for one association (extremely low birth weight vs. normal 20 
birth weight), where we converted Cohen’s d to OR for optimal presentation. Eventually, 21 
metrics used were either RR or OR. Effect size was smaller than 2 except for six associations, 22 
of which three (congenital cytomegalovirus infection, hearing impairment, visual 23 
13 
 
 
impairment) had effect size larger than 10. Only two factors (folic acid supplementation 1 
during pregnancy and breastfeeding) were associated with decreased risk of ASD. 2 
Thirty-one associations (46%) showed large heterogeneity (I2>50%), of which 12 (18%) had 3 
very large heterogeneity (I2>75%). Twenty-four (36%) statistically significant associations 4 
had neither small study effects nor excess significance bias. 95% prediction interval excluded 5 
the null in only 19 (28%) of the associations. Eleven (16%) associations were retrieved from 6 
two individual studies only, and thus small study effects and prediction intervals could not be 7 
estimated. Effect sizes of meta-analyses showed a trend toward null value as the standard 8 
error of summary estimate decreased (figure 2), and effect sizes of the largest studies were 9 
largely similar with the effect sizes of random effects meta-analyses (figure 3). Under the 10 
random effects models, while 52 (78%) associations were statistically significant, 41 (61%), 11 
30 (45%), 18 (27%), and 10 (15%) retained statistical significance under respectively 5%, 12 
10%, 15%, and 20% credibility ceilings.  13 
Eventually, seven (10%) associations were graded as convincing evidence (table 1-2). The 14 
risk factors with convincing associations were the following: maternal age ≥ 35 years vs. 25 15 
to 29 years, maternal chronic hypertension, maternal gestational hypertension, maternal 16 
overweight pre- or during pregnancy, maternal preeclampsia, pre-pregnancy maternal 17 
antidepressant exposure vs. unexposed group, and selective serotonin reuptake inhibitor 18 
(SSRI) during pregnancy. Effect sizes of these associations ranged from 1·31 to 1·84. Eight 19 
(12%) associations were graded as highly suggestive evidence (table 1-2), which are the 20 
following: highest maternal age group vs. reference group, maternal age 30 to 34 vs. 25 to 29 21 
years, maternal autoimmune disease exposure, acetaminophen during pregnancy, higher 22 
paternal age, per 10-year increase, highest paternal age group vs. reference group, paternal 23 
14 
 
 
age>45 years vs. reference group, and paternal age 40-45 years vs. reference group. Eleven 1 
(16%) associations were graded as suggestive evidence (table S2), twenty-six (39%) were 2 
graded as weak evidence (table S3), and the remaining 15 (22%) did not show statistically 3 
significant associations (table S4).  4 
Fifty-two associations of biomarkers comprised a total of 15614 cases and 15417 controls 5 
(table 3,S6,S7). Out of 52 meta-analyses of environmental risk factors, 17 (33%) used case-6 
control studies. Two (4%) associations used cross-sectional studies, and study design was not 7 
specified in 33 (63%) studies. The median number of study estimates in each analysis was six 8 
(range 2–23). The median number of cases and controls was 228 and 215·5.  9 
Out of 52 biomarkers associations, twenty-seven (52%) associations were statistically 10 
significant (p value < 0·05), and ten (19%) associations had p value < 10-3. Only three 11 
associations, 5-hydroxytryptamine in whole blood, digit ratio (2D:4D ratio), and glutathione 12 
disulfide in plasma had p value < 10-6. Moreover, only three associations, namely brain-13 
derived neurotrophic factor in blood, mercury in hair, and mercury in whole blood, were 14 
supported by a population with more than 1,000 ASD cases. No associations were based on 15 
more than 1,000 cases had p value < 10-3. Thus, no biomarker association was graded as 16 
suggestive (class III) or higher level of evidence.  17 
Out of 27 statistically significant associations, only 14 were also supported by a statistically 18 
significant result of the largest component study, of which none was supported by a 19 
statistically significant result of the largest study of standard error < 0·10. Forty-four 20 
associations (85%) had large heterogeneity (I2>50%), of which 36 (69%) associations had 21 
very large heterogeneity. Only eleven (21%) associations retained statistical significance 22 
under 10% credibility ceilings, and twelve (23%) statistically significant associations had 23 
15 
 
 
neither small study effects nor excess significance bias. 95% prediction intervals excluded the 1 
null in only one association (D2:D4 ratio). The detailed results are summarized in table S6-S7.  2 
Sensitivity subset analyses were performed on meta-analyses of 15 environmental risk factors 3 
graded as convincing (class I) or highly suggestive evidence (class II). Subset analysis 4 
restricted to cohort studies (prospective or retrospective) showed that only two associations of 5 
class I remained at the same rank (table S8). These were maternal overweight pre- or during 6 
pregnancy and maternal preeclampsia. Three associations (SSRI during pregnancy, 7 
acetaminophen during pregnancy, paternal age>45 years vs. reference group) remained at 8 
highly suggestive evidence. When subset analysis was restricted to only prospective cohort 9 
studies, no convincing association was identified, and only two associations (maternal 10 
overweight pre- or during pregnancy and SSRI during pregnancy) were still graded as highly 11 
suggestive evidence (table S9).  12 
In subset analyses of adjusted study estimates, association of maternal preeclampsia with 13 
ASD was downgraded to suggestive evidence, while association of maternal autoimmune 14 
disease exposure with ASD was upgraded from highly suggestive evidence to convincing 15 
evidence (table S10). In subset analyses limited to component studies that used diagnostic 16 
methods in line with DSM III-V or ICD-8/9/10, only two associations, maternal gestational 17 
hypertension and maternal autoimmune disease exposure, were downgraded to suggestive 18 
evidence (table S11). 19 
A total of 46 associations were eligible for subgroup analyses of cohort studies and case-20 
control studies (table S12). It is worth noting that in all nine class I or II associations that had 21 
their level of evidence downgraded in subset analyses of cohort studies (table S8), the effect 22 
difference between subgroups of cohort studies and case-control studies was not significant. 23 
16 
 
 
Therefore, in these associations, adopting the results and level of evidence of the original 1 
meta-analyses of both cohort and case-control studies would also be appropriate. In nine 2 
eligible environmental risk factors, at least one individual study reported adjusted study 3 
estimates separately by sex or presence of intellectual disability (table S13). Separate meta-4 
analyses by these factors were not feasible due to lack of study estimates (table S13). 5 
 6 
7 
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DISCUSSION 1 
To the best of our knowledge, the current umbrella review is the first to quantitively appraise 2 
the environmental risk factors and biomarkers of ASD. We evaluated associations of ASD 3 
with 119 possible risk factors and biomarkers. Our analysis revealed that associations 4 
showing convincing evidence (class I) were either maternal factors, such as age and features 5 
of metabolic syndrome, or use of antidepressants such as SSRI. Association of ASD with 6 
higher paternal age, maternal autoimmune disease exposure, and acetaminophen exposure 7 
during pregnancy were graded as highly suggestive evidence (class II), partly because of the 8 
presence of small study effects and large heterogeneity. Only two associations, maternal 9 
overweight pre- or during pregnancy and SSRI during pregnancy, remained at convincing or 10 
highly suggestive evidence. However, the results should be interpreted with caution, because 11 
the statistical methods and bias tests applied are not perfect and criteria are based on arbitrary 12 
thresholds, although they have been used in recent umbrella reviews of meta-analyses.20-25 13 
In our study, components of a maternal metabolic syndrome, that is, chronic hypertension, 14 
gestational hypertension, preeclampsia, and overweight were associated with higher risk of 15 
ASD in offspring, all graded as convincing evidence. One of the possible underlying 16 
mechanism discussed is “fetal programming”, a concept that maternal factors like 17 
inflammation and chronic stress can alter the gestational environment and determine long 18 
term fetal outcomes.86,87 Metabolic syndromes are often characterized by chronic low-grade 19 
inflammation and insulin resistance. The metabolic and immune system share common 20 
signaling pathways.88 Although the role of an aberrant immune system function in the 21 
development of ASD is speculative, there has been evidence of the deleterious role of 22 
dysregulation of the maternal immune system on the development of ASD.89 Several studies 23 
18 
 
 
showed that maternal autoantibodies that recognize proteins in the developing fetal brain 1 
could cause ASD in offspring of mothers with metabolic syndromes.90,91 In children with 2 
severe ASD, ASD-specific autoantibodies were found to be significantly more prevalent in 3 
mothers with diabetes (type 2 or gestational), hypertension, and mothers who were 4 
moderately overweight than in healthy mothers.92 Recently, Jones et al.90 demonstrated that 5 
ASD-specific antigen-induced maternal autoantibodies produced alterations in a constellation 6 
of ASD-relevant behaviors in mice. Therefore, one hypothesis is that metabolic syndrome 7 
could contribute to the production of ASD-specific maternal autoantibodies through a 8 
breakdown of maternal immune tolerance and this can increase the risk for the development 9 
of ASD in the offspring. 10 
Convincing evidence showed that maternal age, when the comparison is restricted to age 11 
groups of ≥ 35 years vs. 25 to 29 years, was associated with a higher risk of ASD. 12 
Accumulation of mutations, high rate of complications, and increased chance of exposure to 13 
medications or pollutions are possible mechanisms that underlie the higher risk of ASD in 14 
higher maternal age group.80 Higher paternal age was also associated with a higher incidence 15 
of ASD. Three comparisons (per 10-year increase in paternal age, highest paternal age group 16 
vs. reference group, paternal age>45 years vs. reference group, and paternal age 40-45 years 17 
vs. reference group) represented risk factor as higher paternal age showed sufficiently low p 18 
value (< 10-6) and 95% prediction intervals excluded the null despite high heterogeneity and 19 
presence of small study effects. In two of the comparisons, subset analyses of prospective 20 
studies showed p value < 10-3 with no evidence of small study effects, indicating the 21 
existence of meaningful associations. Increased rate of de novo mutations93 and epigenetic 22 
alternations80 are proposed potential mechanisms underlying the association.  23 
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Convincing evidence showed that maternal exposure to SSRI during pregnancy was 1 
associated with a higher risk of ASD when compared with unexposed groups. However, the 2 
association must be interpreted carefully. In another meta-analysis, when maternal groups 3 
with pre-pregnancy antidepressant exposure were compared with unexposed maternal groups, 4 
the association with ASD was also graded as convincing evidence. This raises the question of 5 
whether underlying psychiatric conditions of mothers have caused confounding by indication 6 
in classical comparisons (SSRI-exposed vs. SSRI-unexposed). Several other meta-analytic 7 
attempts have been made to discern between the two possible causes of ASD.53,64 When 8 
maternal groups with psychiatric disorder but with no SSRI exposure during pregnancy were 9 
compared with unexposed groups, a higher incidence of ASD was observed in the former 10 
group (OR=1·81, 95% CI=1·44 to 2·29), supporting the idea that presence of a maternal 11 
psychiatric condition is an independent risk factor for ASD.53 Meanwhile, when SSRI-12 
exposed groups were compared with unexposed groups with a history of affective disorder 13 
(setting in which the possibility of confounding by psychiatric disorder is minimized), the 14 
association with ASD was nonsignificant (OR=1·18, 95% CI=0·91 to 1·52).64 Analyses 15 
restricted to sibling studies also showed a non-significant association (RR=0·96, 95% CI 0·65 16 
to 1·42).64 Interestingly, when group with paternal antidepressant exposure during the 17 
maternal pregnancy period were compared with unexposed group, there was higher risk of 18 
ASD in the former group (RR=1·29, 95% CI=1·08 to 1·53).64 Overall, these findings suggest 19 
that while maternal psychiatric disorder may act as an independent risk factor for ASD, the 20 
association between SSRI exposure during pregnancy and ASD needs to be further verified in 21 
adequately designed future studies. 22 
20 
 
 
Maternal autoimmune disease exposure was associated with higher risk of ASD, graded as 1 
highly suggestive association, with 95% prediction intervals excluding the null. In mothers 2 
with autoimmune diseases, immune response mediators and autoantibodies might play a role 3 
in fetal neurodevelopment, resulting in adverse fetal outcomes such as ASD. Family history 4 
of psoriasis, rheumatoid arthritis, type 1 diabetes, or any type of autoimmune disease was 5 
also associated with a higher risk of ASD, graded as suggestive evidence. Several researchers 6 
have tested the potential link between the production of ASD-specific brain-reactive maternal 7 
autoantibodies and maternal autoimmunity.94,95 Martin et al.94 showed that rhesus monkeys 8 
exposed prenatally to human IgG collected from mothers of multiple children diagnosed with 9 
ASD consistently demonstrated increased whole-body stereotypies and hyperactive behaviors, 10 
suggesting a potential autoimmune etiology in a subgroup of patients with ASD. Brimberg et 11 
al.95 reported that mothers of a child with ASD that were positive for anti-brain antibodies 12 
were significantly more likely to be positive for anti-nuclear autoantibodies, which are 13 
frequently observed in patients with various kinds of autoimmune diseases. They also found 14 
that there was a significantly increased incidence of some autoimmune in mothers with 15 
circulating ASD-specific anti-brain antibodies than those with negative anti-brain 16 
antibodies.95 Despite such findings, in the identified meta-analyses, small study effects 17 
existed across the associations, and no significant association of ASD with maternal 18 
autoimmune disease was identified when the analysis was restricted to certain types of 19 
autoimmune diseases (e.g., autoimmune thyroid disease).44 Therefore, more studies are 20 
needed to confirm the association between maternal autoimmune disease exposure and ASD. 21 
Fifty-two biomarkers for ASD were identified and analyzed. Identifying robust evidence of 22 
biomarker for ASD can result in early diagnosis and better treatment of the disease.96 23 
21 
 
 
Association of D2:D4 ratio with a risk of ASD was supported by sufficiently low p value 1 
(p<10-6) without signs of biases, meeting the criteria for convincing evidence except for the 2 
number of ASD cases, being supported by 277 cases. However, most of the associations of 3 
biomarkers were supported by p values close to the significance threshold (p value>10-3) and 4 
too few cases, implying a significant possibility of false positive findings. Similar findings 5 
were observed in umbrella reviews of biomarkers for other psychiatric disorders.21,97,98 6 
Findings from our study differed significantly from that of the previous umbrella review 7 
which systematically evaluated environmental risk factors for ASD using different 8 
approaches to determine the credibility of the association.7 The previous review concluded 9 
that birth complications accompanied by trauma or ischemia and hypoxia have shown strong 10 
links to ASD, while in our review, those markers were graded as class III evidence (5-min 11 
Apgar score < 7, class III; O2 treatment, class IV; neonatal acidosis, NS) due to p value close 12 
to significance threshold or few cases. These risk factors should be interpreted with caution, 13 
because autism is not thought to be a disorder of brain damage, such as hypoxia, but of 14 
aberrant brain development. Also, we should also consider the populations that were studied 15 
and whether the diagnosis was truly confirmed using objective criteria, because the 16 
broadening of the definition of ASD could result in labeling some individuals with 17 
differences in socialization as having ASD. In addition, because there are many comorbidities 18 
to be considered in evaluating prenatal or perinatal factors, using unadjusted study estimates 19 
in a meta-analysis can lead to overestimation of the results. The previous review also asserted 20 
that pregnancy-related factors such as maternal obesity, maternal diabetes, and caesarian 21 
section have shown weak association with ASD.7 While our review agreed on the listed 22 
associations (maternal obesity, class IV; caesarian section, class IV; maternal diabetes, class 23 
22 
 
 
III), we further concluded that other pregnancy-related maternal factors, such as preeclampsia, 1 
hypertension, and psychiatric disorders were convincingly associated with ASD. In contrast 2 
with the previous review7, our review quantitatively appraised risk factors in terms of not 3 
only small study effects but also other various tests of assessing potential biases. We 4 
discerned between the likely and the less likely associations and graded the credibility of the 5 
associations using objective criteria utilizing rigorous statistical tests developed and 6 
reproduced in prior studies,20-25,39,40 which is why we believe our review provides the most 7 
reliable and objective evidence of associations between environmental risk factors and ASD.  8 
There are some limitations to our study. First, despite the most rigorous criteria we used to 9 
assess the credibility of the associations developed and reproduced in prior studies,20-25 we 10 
cannot be sure we ruled out all the biases inherent to individual studies. In addition, biases 11 
that might have caused from the respective characteristics of study design, diagnosis of ASD, 12 
genetic causes of ASD in the population, or gender effects, were not fully assessed in our 13 
study, partly due to insufficient reporting of the original studies. Second, we did not assess 14 
the quality of component studies of the meta-analyses as it was beyond the scope of our 15 
umbrella review. If component studies are flawed with serious methodologic problems, or if 16 
crude unadjusted study estimates which can be more exaggerated than adjusted study 17 
estimates are used in the meta-analysis, the effect of meta-analysis could be overestimated. 18 
Surely, when we re-analyzed an eligible meta-analysis studying thimerosal exposure during 19 
embryo or early infancy82 after excluding its individual studies known for their flawed 20 
methodology,99,100 the level of association changed from class IV (p < 0·05) to not significant 21 
(p > 0·05). Likewise, the results of meta-analyses should always be interpreted with caution. 22 
Third, we could not assess environmental risk factors of ASD according to important factors 23 
23 
 
 
such as sex or presence of intellectual disability, because most individual component studies 1 
did not report the adjusted estimates separately by these factors. To overcome this limitation, 2 
future observational studies should report adjusted study estimates of risk factors separately 3 
by such factors, and if possible, make raw population data open to researchers. Fourth, we 4 
studied biomarkers and environmental risk factors reported in published meta-analyses and 5 
therefore, associations that have been studied only in large trials could have been missed in 6 
our review. Fifth, because the possibility of genetic/environmental confounding cannot be 7 
ruled out in findings of observational studies, it may be hard to establish causations from 8 
some associations. What were classified as risk factors might actually act as biomarkers that 9 
predict the ascertainment of ASD, rather than being causal factors.  10 
Despite these limitations, this umbrella review covered and mapped the association of ASD 11 
with a wide range of environmental risk factors and biomarkers. Out of 119 identified 12 
associations, only several maternal factors, which are higher age, chronic hypertension, 13 
preeclampsia, gestational hypertension, overweight pre- or during pregnancy, were 14 
convincingly associated with ASD, without any signs of biases. SSRI exposure during 15 
pregnancy was also convincingly associated but confounding from underlying maternal 16 
psychiatric disorders is highly possible. One cannot state that other associations are not 17 
meaningful, but there is still some uncertainty in them that should be resolved. Further well-18 
designed studies with accurate assessment of potential biases are needed to confirm the true 19 
association.  20 
21 
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Research in context panel 1 
 2 
Evidence before this study 3 
Numerous risk factors and biomarkers were shown to have associations with risk of autism 4 
spectrum disorder (ASD) in systematic reviews and meta-analyses. However, some results 5 
have been inconsistent, and it is unclear if the claimed associations are prone to biases in 6 
literature. One systematic review performed by Modabbernia and colleagues has 7 
comprehensively identified and analyzed possible environmental risk factors of ASD and 8 
concluded that birth complications related birth complications accompanied by trauma or 9 
ischemia and hypoxia have shown strong links to ASD, but overall, quantitative analysis was 10 
lacking, and bias assessment was incomplete due to its reliance on previous reports. To 11 
overcome these limitations, we performed an umbrella review of meta-analyses. We searched 12 
PubMed, Embase, Cochrane Database of Systematic Reviews from inception to 10/17/2018 13 
for meta-analyses of observational studies studying any environmental risk factors and 14 
biomarkers of ASD, without language limitations. We used the following keywords: “autis*”, 15 
“Asperge*”, and “meta-analysis.” We performed various tests of bias assessment and applied 16 
criteria for determining the level of credibility of the association. 17 
Added value of this study 18 
A total of 119 unique associations of environmental risk factors or biomarkers with risk of 19 
ASD were identified and analyzed. Among these, only maternal factors, namely greater age, 20 
chronic hypertension, preeclampsia, gestational hypertension, and overweight pre- or during 21 
pregnancy, were convincingly associated with an increased risk of ASD. Selective serotonin 22 
reuptake inhibitor (SSRI) exposure during pregnancy was also convincingly associated with 23 
increased risk of ASD, but confounding from underlying maternal psychiatric disorder is 24 
possible. Evidence from biomarkers was limited, supported by few cases and p value close to 25 
significance threshold.  26 
Implications of all the available evidence 27 
Our findings suggest that offspring of mothers who are older, having certain metabolic 28 
syndromes, and perhaps under psychiatric disorders are at higher risk of developing ASD. 29 
While this does not imply that the other environmental risk factors and biomarkers are not 30 
26 
 
 
meaningful, there is still some uncertainty in them that should be resolved. Well-designed 1 
prospective cohort studies are needed to draw firmer conclusions. 2 
 3 
4 
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Figure legends 1 
Fig 1. Flow chart of literature searches 2 
Fig 2. Summary estimate of random effects meta-analysis of environmental risk factors 3 
versus standard error. The Y-axis labelled “Standard error” represents the standard error of 4 
random effects summary estimate of each meta-analysis. The X-axis labelled “ Summary 5 
estimate under random effects model (log scale)” represents the the summary estimate under 6 
random effects of each meta-analysis, presented in log scale. The three outliers having  7 
summary estimate>5 are associations of autism spectrum disorder with congenital 8 
cytomegalovirus infection, hearing impairment, and visual impairment. These studies were 9 
not funded by industry nor did the authors declare any conflict of interest.  10 
Fig 3. Log (effect size of the largest study) versus log (summary effect under random effects 11 
model) for each meta-analysis of environmental risk factors. The Y-axis labelled “Log (effect 12 
size of the largest study)” represents the log of the effect estimate of the largest component 13 
study (study with smallest standard deviation) of each meta-analysis. The X-axis labelled 14 
“Log (summary estimate under random effects model)” represents the log of the summary 15 
effect estimate under random effects of each meta-analysis. The three outliers having log of 16 
the summary estimate>2 are associations of autism spectrum disorder with congenital 17 
cytomegalovirus infection, hearing impairment, and visual impairment. These studies were 18 
not funded by industry nor did the authors declare any conflict of interest. 19 
 20 
